FluoGuide A/S (SE:FLUO)

:FLUO

FLUO

FluoGuide A/S

RESEARCH TOOLSreports

FluoGuide A/S (FLUO) Price & Analysis

1 Followers

FLUO Stock Chart & Stats

kr36.00

-kr1.70(-3.82%)

At close: Mar 06 4:00 PM EST

kr36.00

-kr1.70(-3.82%)

Day’s Range― - ―

52-Week Rangekr28.00 - kr47.60

Previous CloseN/A

Volume5.01K

Average Volume (3M)8.21K

Market Cap

kr624.54M

Enterprise Valuekr370.10M

Total Cash (Recent Filing)kr78.84M

Total Debt (Recent Filing)kr28.30M

Price to Earnings (P/E)―

Beta0.33

Next Earnings

Jun 03, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.28

Shares Outstanding16,349,314

10 Day Avg. Volume11,579

30 Day Avg. Volume8,206

Financial Highlights & Ratios

PEG Ratio-0.29

Price to Book (P/B)6.10

Price to Sales (P/S)0.00

P/FCF Ratio-8.79

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-3.08

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Equity Capital BufferA materially larger equity base provides a durable capital buffer to absorb development losses and extend runway without immediate insolvency risk. This strengthens the company’s ability to fund clinical programs or seek strategic partnerships over the next 2–6 months while avoiding immediate cash-collapse scenarios.

Positive Gross-profit In Revenue YearsPositive gross profit indicates the product itself has favorable unit economics when sales occur. That supports a sustainable margin profile at scale because consumable per-dose sales can generate contribution margin, improving prospects for operating leverage once fixed R&D and SG&A are controlled.

Focused Asset And Partner-friendly ModelA single, focused clinical-stage asset (FG001) designed to work with existing imaging systems reduces commercialization complexity. The consumable licensing/partnering model is structurally attractive, enabling the company to outsource manufacturing and commercialization to larger partners and scale revenue without heavy capex.

Bears Say

Persistent Heavy Cash BurnLarge, sustained negative operating cash flows force continued external financing, increasing dilution and creating ongoing funding risk. Over the medium term this constrains investments in pivotal trials or commercialization, and makes the company dependent on capital markets or partners to avoid cutting programs.

Collapsing And Volatile RevenueThe collapse to effectively zero reported revenue in 2025 shows weak sales traction or timing failures in commercialization. Without demonstrable recurring consumable sales, the long-term case for sustainable margins and predictable cash generation is highly uncertain, complicating partner negotiations and forecasting.

Sharp Rise In LeverageA sudden increase in debt materially raises fixed obligations and refinancing risk, especially given persistent losses and cash burn. Higher leverage reduces strategic flexibility, may increase cost of capital, and could force unfavorable deal terms or accelerated dilution if operating performance does not improve.

FLUO FAQ

What was FluoGuide A/S’s price range in the past 12 months?

FluoGuide A/S lowest stock price was kr28.00 and its highest was kr47.60 in the past 12 months.

What is FluoGuide A/S’s market cap?

FluoGuide A/S’s market cap is kr624.54M.

When is FluoGuide A/S’s upcoming earnings report date?

FluoGuide A/S’s upcoming earnings report date is Jun 03, 2026 which is in 48 days.

How were FluoGuide A/S’s earnings last quarter?

FluoGuide A/S released its earnings results on Feb 25, 2026. The company reported -kr1.278 earnings per share for the quarter, missing the consensus estimate of N/A by -kr1.278.

Is FluoGuide A/S overvalued?

According to Wall Street analysts FluoGuide A/S’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does FluoGuide A/S pay dividends?

FluoGuide A/S does not currently pay dividends.

What is FluoGuide A/S’s EPS estimate?

FluoGuide A/S’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does FluoGuide A/S have?

FluoGuide A/S has 16,349,314 shares outstanding.

What happened to FluoGuide A/S’s price movement after its last earnings report?

FluoGuide A/S reported an EPS of -kr1.278 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of FluoGuide A/S?

Currently, no hedge funds are holding shares in SE:FLUO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

FluoGuide A/S

FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. Its lead product candidate is FG001, which is in Phase I/II for the treatment of high-grade glioma, as well as Phase II clinical trial for the treatment of lung cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. FluoGuide A/S has an agreement with Linköping University Hospital for the development of FG001 that is in the Phase I/II clinical trial for surgical removal of brain cancer; and a collaboration with Copenhagen University Hospital. The company was incorporated in 2018 and is headquartered in Copenhagen, Denmark.